The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Flagged first, then by citations
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 901–1,000 of 1,053
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights
Xue, G., Romano, E., Massi, D., & Mandalà, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.009 · Cited by 113
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J. L., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 111
“However, we speculate that the resistance of physiological MAPK signaling to both RAF and MEK inhibitors might explain why these drugs spare normal cells and are well tolerated in patients (Chapman et al., 2011; Flaherty et al., 2012).”
BackgroundBRAF Gene and Melanoma: Back to the Future
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 125
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 116
Natural products for combating multidrug resistance in cancer
Chen, T., Xiao, Z., Liu, X., Wang, T., Wang, Y., Ye, F., Su, J., Yao, X., Xiong, L., & Yang, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107099 · Cited by 118
Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
Deng, W., Gopal, Y. N. V., Scott, A., Chen, G., Woodman, S. E., & Davies, M. A. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00950.x · Cited by 113
Hong, D. S., Vence, L. M., Falchook, G. S., Radvanyi, L. G., Liu, C., Goodman, V. L., Legos, J. J., Blackman, S., Scarmadio, A., Kurzrock, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2515 · Cited by 109
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
Cooper, Z. A., Frederick, D. T., Juneja, V. R., Sullivan, R. J., Lawrence, D. P., Piris, A., Sharpe, A. H., Fisher, D. E., Flaherty, K. T., & Wargo, J. A. (2013) · OncoImmunology · doi:10.4161/onci.26615 · Cited by 109
Self-citationSentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis
Cordeiro, E., Gervais, M., Shah, P., Hong, N. L., & Wright, F. C. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5137-z · Cited by 51
Jochems, A., Schouwenburg, M. G., Leeneman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Gelderblom, H. A. J., Groot, C. A. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.021 · Cited by 107
Self-citationStrategies to design clinical studies to identify predictive biomarkers in cancer research
Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112
Mechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 112
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 115
Accelerating the understanding of cancer biology through the lens of genomics
Wang, D., Liu, B., & Zhang, Z. (2023) · Cell · doi:10.1016/j.cell.2023.02.015 · Cited by 116
Circulating Cell-Free Tumour DNA in the Management of Cancer
Francis, G. D., & Stein, S. R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160614122 · Cited by 112
Trietsch, M. D., Nooij, L. S., Gaarenstroom, K. N., & van Poelgeest, M. I. E. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.11.002 · Cited by 108
Johnson, D. B., Dahlman, K. H., Knol, J., Gilbert, J., Puzanov, I. J., Means-Powell, J. A., Balko, J. M., Lovly, C. M., Murphy, B. A., Goff, L. W., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0011 · Cited by 109
Self-citationTalimogene Laherparepvec for the Treatment of Advanced Melanoma
Ott, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2709 · Cited by 111
Gouda, M. A., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100788 · Cited by 115
“Moreover, single-agent inhibitors have been associated with the development of secondary skin cancers which was linked to activation of the MAPK pathway that can happen with monotherapy.(18,68) Most of the current approved combination options include a BRAF and a MEK inhibitor.”
BackgroundRecurrent inactivating RASA2 mutations in melanoma
Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J. S., Gartner, J. J., Di Pizio, A., Winograd-Katz, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3427 · Cited by 107
Current State of Animal (Mouse) Modeling in Melanoma Research
Kuzu, O. F., Nguyen, F. D., Noory, M. A., & Sharma, A. K. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s21214 · Cited by 121
Challenging resistance mechanisms to therapies for metastatic melanoma
Tentori, L., Lacal, P. M., & Graziani, G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.003 · Cited by 114
Boursault, L., Haddad, V., Vergier, B., Cappellen, D., Verdon, S., Bellocq, J., Jouary, T., & Merlio, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070826 · Cited by 108
Self-citationVaidhyanathan, S., Mittapalli, R. K., Sarkaria, J. N., & Elmquist, W. F. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058339 · Cited by 107
Hoefflin, R., Geißler, A.-L., Fritsch, R., Claus, R., Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D. H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00105 · Cited by 114
Mitochondrial Respiration - An Important Therapeutic Target in Melanoma
de Moura, M. B., Vincent, G., Fayewicz, S. L., Bateman, N. W., Hood, B. L., Sun, M., Suhan, J. P., Duensing, S. M., Yin, Y., Sander, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040690 · Cited by 105
Self-citationPenman, C. L., Faulkner, C., Lowis, S. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00054 · Cited by 107
Sharma, A., Shah, S. R., Illum, H., & Dowell, J. E. (2012) · Drugs · doi:10.2165/11640870-000000000-00000 · Cited by 108
Vemurafenib and radiation therapy in melanoma brain metastases
Narayana, A., Mathew, M., Tam, M. M., Kannan, R., Madden, K. M., Golfinos, J. G., Parker, E. C., Ott, P. A., & Pavlick, A. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1127-1 · Cited by 105
Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
van der Noll, R., Leijen, S., Neuteboom, G. H. G., Beijnen, J. H., & Schellens, J. H. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.003 · Cited by 106
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 108
Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 107
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V. R., Yan, J. J., Pham, L. Q., Wang, M. M., Bollag, G. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 104
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 109
Woodman, S. E. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824bd256 · Cited by 108
Choong, E. S., Lo, S., Drummond, M., Fogarty, G. B., Menzies, A. M., Guminski, A. D., Shivalingam, B., Clarke, K., Long, G. V., & Hong, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.007 · Cited by 106
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 110
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
Takahashi, M., Chong, H. B., Zhang, S., Yang, T.-Y., Lazarov, M. J., Harry, S. A., Maynard, M., Hilbert, B. J., White, R. D., Murrey, H. E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.027 · Cited by 110
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
Friedman, K. M., Prieto, P. A., Devillier, L., Gross, C. A., Yang, J. C., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825898c5 · Cited by 106
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*
Stuart, S. A., Houel, S., Lee, T., Wang, N., Old, W. M., & Ahn, N. G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047233 · Cited by 116
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W. A., Thompson, J. F., Kefford, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.287 · Cited by 105
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 111
Targeting Oncogenic Drivers and the Immune System in Melanoma
McArthur, G. A., & Ribas, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5568 · Cited by 108
Self-citationMassi, D., Brusa, D., Merelli, B., Falcone, C., Xue, G., Carobbio, A., Nassini, R., Baroni, G., Tamborini, E., Cattaneo, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv255 · Cited by 105
Harbst, K., Lauss, M., Cirenajwis, H., Isaksson, K., Rosengren, F., Törngren, T., Kvist, A., Johansson, M. C., Vallon‐Christersson, J., Baldetorp, B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3476 · Cited by 108
Ott, P. A., Henry, T., Baranda, S. J., Frleta, D., Manches, O., Bogunovic, D., & Bhardwaj, N. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1389-z · Cited by 106
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Cassidy, M. R., Wolchok, R. E., Zheng, J., Panageas, K. S., Wolchok, J. D., Coit, D. G., Postow, M. A., & Ariyan, C. E. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.029 · Cited by 105
Tan, O., Shrestha, R. N., Cunich, M. M., & SCHOFIELD, D. J. (2017) · Clinical Genetics · doi:10.1111/cge.13199 · Cited by 106
McEvoy, A. C., Warburton, L., Al‐Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., Khattak, M. A., Meniawy, T. M., Millward, M., Ziman, M. R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4637-6 · Cited by 107
Nuclear factor of activated T cells in cancer development and treatment
Shou, J., Jing, J., Xie, J., You, L., Zhao, J., Yao, J., Han, W., & Pan, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.005 · Cited by 106
Cui, C., Mao, L., Chi, Z., Si, L., Sheng, X., Kong, Y., Li, S., Lian, B., Gu, K., Tao, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.79 · Cited by 102
The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
Ekedahl, H., Cirenajwis, H., Harbst, K., Carneiro, A., Nielsen, K., Olsson, H. L., Lundgren, L., Ingvar, C., & Jonsson, G. G. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12504 · Cited by 104
Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis
Charles, R., Silva, J. M., Iezza, G., Phillips, W. A., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0158-t · Cited by 104
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Zheng, G., Tseng, L., Chen, G., Haley, L. M., Illei, P. B., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1811-y · Cited by 105
Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., Shinn, L., Kelley, M. C., Joseph, R. W., & Sosman, J. A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0092 · Cited by 104
Self-citationDramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma
Peters, S., Michielin, O. A., & Zimmermann, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6143 · Cited by 104
Ascierto, P. A., Simeone, E., Chiarion‐Sileni, V., Vecchio, M. D., Marchetti, P., Cappellini, G. C. A., Ridolfi, R., Rosa, F. D., Cognetti, F., Ferraresi, V., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.885984 · Cited by 103
Self-citationBUSAM, K. J., Hedvat, C. V., Pulitzer, M. P., von Deimling, A., & Jungbluth, A. A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318271249e · Cited by 104
Cesi, G., Walbrecq, G., Zimmer, A. D., Kreis, S., & Haan, C. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0667-y · Cited by 108
Li, Z., Zhao, L., Yu, L., & Wei, M. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa022 · Cited by 110
“hibitor vemurafenib elicits a good response in 60%–80% of patients with BRAF-mutant melanoma in clinical trials [98, 99].”
BackgroundJACKS: joint analysis of CRISPR/Cas9 knockout screensPreprint
Allen, F. R., Behan, F. M., Khodak, A., Iorio, F., Yusa, K., Garnett, M. J., & Parts, L. (2019) · Genome Research · doi:10.1101/gr.238923.118 · Cited by 101
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 106
Paraiso, K. H. T., Thakur, M. D., Fang, B., Koomen, J. M., Smalley, I., John, J. K., Tsao, H., Flaherty, K. T., Sondak, V. K., Messina, J. L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0293 · Cited by 102
Self-citationPersonalizing health care: feasibility and future implications
Godman, B., Finlayson, A. E. T., Cheema, P. K., Zebedin-Brandl, E. M., Gutiérrez‐Ibarluzea, I., Jones, J., Malmström, R. E., Asola, E., Baumgärtel, C., Bennie, M., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-179 · Cited by 107
Malaguarnera, G., Madeddu, R., Catania, V. E., Bertino, G., Morelli, L., Perrotta, R. E., Drago, F., Malaguarnera, M., & Latteri, S. (2018) · Oncotarget · doi:10.18632/oncotarget.23835 · Cited by 109
Schwager, K., Hemmerle, T., Aebischer, D., & Neri, D. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.376 · Cited by 104
Surgery for Distant Melanoma Metastasis
Leung, A. M., Hari, D. M., & Morton, D. L. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824bc981 · Cited by 103
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S.-C., Kim, S. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3751 · Cited by 103
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 105
Bucheit, A. D., Syklawer, E., Jakob, J. A., Bassett, R. L., Curry, J. L., Gershenwald, J. E., Kim, K. B., Hwu, P., Lazar, A. J., & Davies, M. A. (2013) · Cancer · doi:10.1002/cncr.28306 · Cited by 107
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines
Vultur, A., Villanueva, J., Krepler, C., Rajan, G., Chen, Q., Xiao, M., Li, L., Gimotty, P. A., Wilson, M. A., Hayden, J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.131 · Cited by 101
Metronomic chemotherapy for cancer treatment: a decade of clinical studies
Romiti, A., Cox, M. C., Sarcina, I., Rocco, R. D., D’Antonio, C., Barucca, V., & Marchetti, P. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2125-x · Cited by 103
Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
Lucas, K. M., Mohana‐Kumaran, N., Lau, D. T., Zhang, X. D., Hersey, P., Huang, D. C. S., Weninger, W., Haass, N. K., & Allen, J. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1166 · Cited by 105
A Cancer Theory Kerfuffle Can Lead to New Lines of Research
Baker, S. G. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju405 · Cited by 107
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
Jin, T., Lavoie, H., Sahmi, M., David, M., Hilt, C., Hammell, A., & Therrien, M. (2017) · Nature Communications · doi:10.1038/s41467-017-01274-0 · Cited by 101
Buzdin, A. A., Sorokin, M., Garazha, A., Sekacheva, M. I., Kim, E. L., Zhukov, N. V., Wang, Y., Li, X., Kar, S., Hartmann, C. J., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.003 · Cited by 103
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A. P., Emburgh, B. V., Parpart-Li, S. T., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 101
Electrochemotherapy for disseminated superficial metastases from malignant melanoma
Campana, L. G., Valpione, S., D, S. M. M., Sundararajan, R., Granziera, E., Sartore, L., Chiarion‐Sileni, V., & Rossi, C. R. (2012) · British journal of surgery · doi:10.1002/bjs.8749 · Cited by 102
Kinase Inhibitors: Adverse Effects Related to the Endocrine System
Lodish, M. B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4085 · Cited by 103
Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway
Huang, V., Hepper, D. M., Anadkat, M. J., & Cornelius, L. A. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.125 · Cited by 101
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Haq, R., Fisher, D. E., & Widlund, H. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0898 · Cited by 99
Hepatic stellate cells: central modulators of hepatic carcinogenesis
Thompson, A., Conroy, K. P., & Henderson, N. C. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0291-5 · Cited by 103
Harrington, K. J., Andtbacka, R. H. I., Collichio, F. A., Downey, G. F., Chen, L., Szabó, Z. R., & Kaufman, H. L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s115245 · Cited by 104
Perez, M. C., Miura, J. T., Naqvi, S. M. H., Kim, Y., Holstein, A. H., Lee, D. H., Sarnaik, A. A., & Zager, J. S. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6803-0 · Cited by 101
Lü, Y., Ko, M. E., Cheng, H., Zhu, R., Xue, M., Wang, J. K., Lee, J. W., Frankiw, L., Xu, A. M., Wong, S. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15956-9 · Cited by 102
Self-citationMYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
Ensslin, C. J., Rosen, A. C., Wu, S., & Lacouture, M. E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.06.038 · Cited by 102
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
Sakaizawa, K., Goto, Y., Kiniwa, Y., Uchiyama, A., Harada, K., Shimada, S., Saida, T., Ferrone, S., Takata, M., Uhara, H., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.12 · Cited by 103
Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchiocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0022 · Cited by 102
Self-citationKorkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Sümer, S. O., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 99
Haroche, J., Aubart, F. C., Arnaud, L., Hervier, B., Charlotte, F., Drier, A., Gorochov, G., Greniér, P., Cluzel, P., Maksud, P., et al. (2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.04.007 · Cited by 100
Yun, S., Vincelette, N. D., Green, M. R., Hendrickson, A. E. W., & Abraham, I. L. (2016) · Cancer Medicine · doi:10.1002/cam4.732 · Cited by 99
Sun, X., Li, J., Sun, Y., Zhang, Y., Dong, L., Shen, C., Liu, Y., Yang, M., Li, Y., Shen, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10669 · Cited by 103
BRAF V600E mutation in hairy cell leukemia: from bench to bedside
Falini, B., Martelli, M. P., & Tiacci, E. (2016) · Blood · doi:10.1182/blood-2016-07-418434 · Cited by 102
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Young, A., Ngiow, S. F., Madore, J., Reinhardt, J., Landsberg, J., Chitsazan, A., Rautela, J., Bald, T., Barkauskas, D. S., Ahern, E. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0393 · Cited by 101
Self-citationLi, Z., Jiang, K., Zhu, X., Lin, G., Song, F., Zhao, Y., Piao, Y., Liu, J., Cheng, W., Bi, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.015 · Cited by 102
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., Perego, P., Cassinelli, G., Lanzi, C., Testi, M., Rivoltini, L., et al. (2011) · Neoplasia · doi:10.1593/neo.111102 · Cited by 99
Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2680 · Cited by 91
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
